Pharmacological Profiles and Recovery Predictors in Severe COVID-19
Open Access
Abstract
This study analyses the pharmacological profiles of medications administered to critically ill COVID-19 patients to evaluate their efficacy regarding recovery rates and duration of hospitalization. The results demonstrate a significant difference in clinical outcomes. While the administration of Ceftazidime, Ceftriaxone, and Oseltamivir was associated with negative survival trends, Dexamethasone and Favipiravir were associated with a fourfold higher probability of survival in severe cases. Notably, no pharmacological intervention significantly reduced the length of hospital stay; instead, recovery duration was primarily influenced by comorbidities such as obesity, cardiovascular disease, and diabetes. Furthermore, age and preexisting physiological conditions remained primary predictors of mortality. Observational analysis in our study for drug repurposing identified Amikacin, Remdesivir, and Rivaroxaban as potential therapeutic candidates. However, Dexamethasone was identified as the most effective treatment for recovery, likely due to a molecular structure with high potential binding affinity to the SARS-CoV-2 virus. These findings suggest that while specific repurposed drugs offer measurable benefits, patient history remains a critical determinant of outcomes, highlighting the necessity for further research to refine therapies against emerging viral pathogens.Keywords
Funding Information
- Indonesian Ministry of Research, Technology and Higher Education (017/ST-Lit/LPPM-01/KemendikbudRistek/Multi/FF/V/2023)
This publication has 34 references indexed in Scilit:
- Risk and Protective Factors for COVID-19 Morbidity, Severity, and MortalityClinical Reviews in Allergy & Immunology, 2022
- Antibacterial agents used in COVID-19: A systematic review and meta-analysisEnvironmental Sustainability, 2021
- Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacyJournal of Infection and Public Health, 2021
- Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designingBiochemistry and Biophysics Reports, 2021
- Risk factors for death in adult COVID-19 patients: Frailty predicts fatal outcome in older patientsInternational Journal of Infectious Diseases, 2021
- Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of actionBiochemical Pharmacology, 2021
- Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective studyBioorganic Chemistry, 2020
- Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2Current Pharmacology Reports, 2020
- COVID-19 infection: Emergence, transmission, and characteristics of human coronavirusesJournal of Advanced Research, 2020
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell, 2020